ChaitaliNangiaMD

Oncology • Newport Beach, CA

Assistant Professor, Medicine, University of California, Irvine, School of Medicine

Join to view full profile

Dr. Nangia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nangia's full profile

Already have an account?

Office
1 Hoag Drive
Newport Beach, CA 92663
Phone+1 949-764-5347

Fax+1 949-557-0221

Education & Training

Henry Ford Health/Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 1999 - 2002
Lady Hardinge Medical CollegeClass of 1998

Certifications & Licensure

CA State Medical License 2011 - 2025
MI State Medical License 2002 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies Start of enrollment: 2021 Sep 08
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
2 citations
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.
Katayoun Moini, Tara Seery, Chaitali Nangia, Jennifer MacDiarmid, Himanshu Brahmbhatt
The Oncologist. 2024-10-04

Journal Articles

Single-Cell Transcriptomes Reveal the Mechanism for a Breast Cancer Prognostic Gene Panel
Chaitali S Nangia, Lilibeth Torno, William G Loudon, Mustafa H Kabeer, Ashley S Plant, Shengwen Calvin Li, Oncotarget

Lectures

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with th...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

$NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy with Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS$
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy with Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCSDecember 16th, 2019